Corcept Therapeutics presented comprehensive data from the randomized, double-blind, placebo-controlled treatment phase of its CATALYST trial at the American Diabetes Association's 85th Scientific Sessions, with simultaneous publication in Diabetes Care. The study confirmed that Korlym significantly improved hemoglobin A1c (HbA1c) in patients with hypercortisolism and difficult-to-control type 2 diabetes.
Patients treated with Korlym experienced a 1.47 percent decrease in HbA1c from baseline, compared to a 0.15 percent decrease in the placebo group (p-value: < 0.001). For patients receiving the 900mg dose, the improvement in HbA1c was 2.01 percent. The trial also met secondary endpoints, showing significant reductions in body weight (5.1 kg; p-value: 0.001) and waist circumference (5.1 cm; p-value: 0.002).
These improvements were achieved even as patients reduced or discontinued other glucose-lowering medications. The adverse events were manageable and consistent with Korlym's known safety profile. These findings provide important guidance for physicians, advocating for screening and cortisol-directed therapy in patients with difficult-to-control type 2 diabetes.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.